[educational] For pure cognitive enhancement, Semax is generally preferred over Selank; Selank is the pick when anxiety is the dominant complaint (its nootropic effect is milder). — Selank deep dive
[regulatory]US status shifting (2026): Semax was removed from FDA Category 2 (Feb 2026) and is on the FDA PCAC 503A agenda for July 24 2026 — FDA’s evaluated uses are cerebral ischemia, migraine, and trigeminal neuralgia (its Russian stroke-neurology heritage, not “nootropic”). Advisory/non-binding; not FDA-approved. — SOURCE-fda-pcac-503a-peptide-review-2026